New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - aldesleukin 18 miu (interleukin-2 (recombinant human));   - powder for injection - 18 miu - active: aldesleukin 18 miu (interleukin-2 (recombinant human))   excipient: dibasic sodium phosphate dihydrate mannitol monobasic sodium phosphate dihydrate sodium laurilsulfate - proleukin is indicated for the treatment of metastatic renal cell carcinoma (mrcc).

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - cladribine 1 mg/ml - solution for infusion - 1 mg/ml - active: cladribine 1 mg/ml excipient: sodium chloride water for injection - leustatin is indicated in the treatment of patients with hairy cell leukaemia (hcl).

Singapore - English - HSA (Health Sciences Authority)

link healthcare singapore pte ltd - aldesleukin - injection, powder, for solution - 18 miu/vial - aldesleukin 18 miu/vial

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - aldesleukin 9 miu (interleukin-2 (recombinant human)) - powder for injection - 9 miu - active: aldesleukin 9 miu (interleukin-2 (recombinant human)) excipient: dibasic sodium phosphate dibasic sodium phosphate monohydrate mannitol sodium laurilsulfate

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - cladribine, quantity: 10 mg - injection, concentrated - excipient ingredients: dibasic sodium phosphate heptahydrate; phosphoric acid; water for injections; sodium chloride - leustatin is indicated for the treatment of patients with hairy cell leukaemia. it is also indicated for the treatment of patients with b-cell chronic lymphocytic leukaemia in whom treatment with alkylating agents has failed.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - other antineoplastic agents - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse.• adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy.• adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

United States - English - NLM (National Library of Medicine)

guna spa - interleukin-10 (unii: 9sc4o216v9) (interleukin-10 - unii:9sc4o216v9) - interleukin-10 4 [hp_c] in 30 ml - interleukin-10    4c    chronic pain relief chronic pain relief directions : take 15 minutes before meals.

United States - English - NLM (National Library of Medicine)

guna spa - interleukin-3 (unii: a802907mi4) (interleukin-3 - unii:a802907mi4) - interleukin-3 4 [hp_c] in 30 ml - interleukin-3  4c  hematopoiesis support hematopoiesis support take 15 minutes before meals.

United States - English - NLM (National Library of Medicine)

guna spa - interleukin-7 (unii: 418xb47y71) (interleukin-7 - unii:418xb47y71) - interleukin-7 4 [hp_c] in 30 ml - interleukin 7   4c   recurrent infections recurrent infections take 15 minutes before meals

United States - English - NLM (National Library of Medicine)

guna spa - interleukin-9 (unii: ey7fq27i5k) (interleukin-9 - unii:ey7fq27i5k) - interleukin-9 4 [hp_c] in 30 ml - interleukin-9   4c   bronchial hyperreactivity bronchial hyperreactivity take 15 minutes before meals.